Shandong Xinhua (00719): Xinda Pharmaceuticals has obtained the registration certificate for ibuprofen granules medication.

SHANDONG XINHUA (00719) announced that its wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical Co., Ltd. (hereinafter referred to as "Xinda Pharmaceutical") has recently received the approval and issuance of the Ibuprofen Granules (hereinafter referred to as the "Product") Drug Registration Certificate from the National Medical Products Administration. In December 2023, Xinda Pharmaceutical submitted the application for the registration of Ibuprofen Granules to the Center for Drug Evaluation of the National Medical Products Administration (CDE) and it was accepted. In March 2026, the company obtained the Drug Registration Certificate, and the evaluation result approved the registration. The Product is used to relieve mild to moderate pain, such as headaches, joint pain, migraines, toothaches, muscle pain, neuralgia, and menstrual pain. It can also be used for fever caused by common colds or influenza. The Ibuprofen Granules are classified as a Category B drug in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List" (2025 edition). According to relevant statistics, the sales of Ibuprofen-related dosage forms in Chinese public medical institutions in 2024 were approximately RMB 4.4 billion.